Canbridge Pharmaceuticals Inc (1228)

Currency in HKD
0.98
+0.01(+1.03%)
Closed·

1228 Financial Summary

Key Ratios

P/E Ratio-0.68
Price/Book-0.64
Debt / Equity-28.62%
Return on Equity172.13%
Dividend Yield0.00%
EBITDA-326.80M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
-0.46 / --
Revenue / Forecast
40.31M / --
EPS Revisions
Last 90 days

FAQ

What were Canbridge Pharmaceuticals's earnings for the latest quarter?

The Canbridge Pharmaceuticals EPS (TTM) is -1.04. Canbridge Pharmaceuticals reported sales of 40.31, net income of -195.35, and EPS of -0.46 for the latest quarter.

What was Canbridge Pharmaceuticals's net income for the latest quarter?

Canbridge Pharmaceuticals's net income for the latest quarter was -195.35.

How did Canbridge Pharmaceuticals's performance compare year-over-year in the latest quarter?

The company's revenue moved from 44.79 in the previous quarter to 40.31 in the latest quarter, and net income moved from -247.27 to -195.35 compared to the previous quarter.

What is Canbridge Pharmaceuticals's net profit margin on a TTM basis?

Canbridge Pharmaceuticals's trailing twelve months (TTM) net profit margin is -520.10%.

How does Canbridge Pharmaceuticals's debt to equity ratio compare to industry standards?

Canbridge Pharmaceuticals's total debt-to-equity ratio is -28.62%.

What is Canbridge Pharmaceuticals's return on investment on a TTM basis?

Canbridge Pharmaceuticals's trailing twelve months (TTM) return on investment (ROI) is 172.13%.

Did Canbridge Pharmaceuticals gain or lose cash last quarter?

In the latest quarter, Canbridge Pharmaceuticals's net change in cash was -45.00 million.

What were Canbridge Pharmaceuticals's total assets and liabilities in the latest quarter?

As of the latest quarter, Canbridge Pharmaceuticals reported total assets of 116.81 million and total liabilities of 482.61 million.

How has Canbridge Pharmaceuticals's total revenue grown this year?

Canbridge Pharmaceuticals's total revenue was 44.79 in the previous quarter and 40.31 in the latest quarter.

What is Canbridge Pharmaceuticals's gross margin on a TTM basis?

Canbridge Pharmaceuticals's trailing twelve months (TTM) gross margin is 63.81%.

What was Canbridge Pharmaceuticals's revenue per share for the latest quarter?

Canbridge Pharmaceuticals's revenue per share for the latest quarter was 5.49.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.